Cart
sales@molnova.com
Atrosab
CAS No. 1365659-05-7
Atrosab( —— )
Catalog No. M37265 CAS No. 1365659-05-7
Atrosab is a humanized IgG1 antibody targeting TNFR1, inhibiting TNF-mediated apoptosis, and can be used to study inflammatory and neurodegenerative diseases.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 588 | In Stock |
|
| 10MG | 938 | In Stock |
|
| 25MG | 1397 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameAtrosab
-
NoteResearch use only, not for human use.
-
Brief DescriptionAtrosab is a humanized IgG1 antibody targeting TNFR1, inhibiting TNF-mediated apoptosis, and can be used to study inflammatory and neurodegenerative diseases.
-
DescriptionAtrosab is a humanized IgG1 antagonistic anti-TNFR1 antibody. Atrosab inhibits TNF-mediated apoptosis induction and IL-6 and IL-8 production. Atrosab can be used for research of inflammatory disease.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayApoptosis
-
TargetApoptosis
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1365659-05-7
-
Formula Weight146.12 kDa.
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Zettlitz KA, et al. ATROSAB, a humanized antagonistic anti-tumor necrosis factor receptor one-specific antibody. MAbs. 2010 Nov-Dec;2(6):639-47.?
molnova catalog
related products
-
FR054 (b)
FR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect.
-
Kinetin riboside
A cytokinin analog that displays potent antiproliferative activity against various human cancer cell lines.
-
CMLD-2
CMLD-2 is an inhibitor of HuR-ARE interaction (Ki: 350 nM) that competitively binds HuR protein and disrupts its interaction with adenine element-rich (ARE) mRNA targets.
